Corporate Updates

Opto Circuits Launches Heart Device for Indian Market

Opto Eurocor Healthcare, a subsidiary of Opto Circuits (India), launched Sirolimus Drug Eluting Stent (DES), E-Magic Plus on receipt of Drug Controller General of India (DCGI) license to sell and market the product in India.

A stent is a wire metal mesh tube that is used to open a blocked artery during an angioplasty.

“E-Magic Plus has been developed indigenously in India and with the DCGI mark we can market and sell in India. The DCGI approval will also enable E-Magic Plus to be marketed in parts of Far East and parts of Middle East,” Opto Circuits (India) Ltd Chairman & Managing Director Vinod Ramnani said.

Sirolimus DES market is estimated to be worth Rs 800 crore in India, he added.

The DES market has two major drug categories: Sirolimus and Paclitaxel. In India, Sirolimus-based angioplasty devices have a more than 90 percent market share, the company said. “Opto Eurocor Healthcare Ltd will launch E-Magic Plus in the European and Latin-American market after receiving the necessary approvals,” it added.

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on


Most Popular

SUBSCRIBE OUR NEWSLETTER
200000+ Subscribers read it every day.
Subscribe Newsletter
To Top